Quantifying factors for the success of stratified medicine
- 31 October 2011
- journal article
- review article
- Published by Springer Nature in Nature Reviews Drug Discovery
- Vol. 10 (11) , 817-833
Abstract
Co-developing a drug with a diagnostic to create a stratified medicine — a therapy that is targeted to a specific patient population on the basis of a clinical characteristic such as a biomarker that predicts treatment response — presents challenges for product developers, regulators, payers and physicians. With the aim of developing a shared framework and tools for addressing these challenges, here we present an analysis using data from case studies in oncology and Alzheimer's disease, coupled with integrated computational modelling of clinical outcomes and developer economic value, to quantify the effects of decisions related to key issues such as the design of clinical trials. This illustrates how such analyses can aid the coordination of diagnostic and drug development, and the selection of optimal development and commercialization strategies. It also illustrates the impact of the interplay of these factors on the economic feasibility of stratified medicine, which has important implications for public policy makers.Keywords
This publication has 50 references indexed in Scilit:
- Crizotinib inALK-Rearranged Inflammatory Myofibroblastic TumorNew England Journal of Medicine, 2010
- Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung CancerNew England Journal of Medicine, 2010
- Targeting the Mitogen-Activated Protein Kinase Pathway: Physiological Feedback and Drug ResponseClinical Cancer Research, 2010
- A Perspective on Challenges and Issues in Biomarker Development and Drug and Biomarker CodevelopmentJNCI: Journal of the National Cancer Institute, 2009
- Use of Archived Specimens in Evaluation of Prognostic and Predictive BiomarkersJNCI: Journal of the National Cancer Institute, 2009
- The clinical meaningfulness of ADAS-Cog changes in Alzheimer's disease patients treated with donepezil in an open-label trialBMC Neurology, 2007
- BRAF mutation predicts sensitivity to MEK inhibitionNature, 2005
- Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast CancerNew England Journal of Medicine, 2005
- Hallmarks of 'BRCAness' in sporadic cancersNature Reviews Cancer, 2004
- Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/neuOncogeneScience, 1987